㈼−2- 10 |
カフェイン(単独,併用)は片頭痛治療に有効か |
論文抄録 |
Tolfenamic acid is a fenamate which inhibits prostaglandin (PG) biosynthesis and may act as a PG antagonist as well. Caffeine and metoclopramide are used in combination with analgesics and ergotamine in the treatment of migraine attacks, but controlled clinical studies on fixed combinations with analgesics are rare. The effects of orally given tolfenamic acid(200 mg), caffeine (100 mg), metoclopramide (10 mg), tolfenamic acid + caffeine (200 mg +100 mg), tolfenamic acid + metoclopramide (200 mg + 10 mg) and placebo were studied in 49 migraine patients (3 men, 46 women) in a double-blind randomized cross-over study comprising 482 migraine attacks. The patients were allowed to take either one or two capsules of each preparation for an attack. Additional drugs were allowed after 3 h. Parameters characterizing the effects and side-effects of the drugs were registered. Tolfenamic acid and its combinations were found to be effective in the treatment of acute migraine, but caffeine and metoclopramide alone did not differ from placebo. Combination with metoclopramide was better than tolfenamic acid alone as judged by the smaller dose needed and the intensity of attack. Between tolfenamic acid alone and its caffeine combination there were no statistically significant differences. o A nalgesic combinations, |
文献 PubMed−ID |
PMID: 6984358 |
エビデンスレベル |
㈵ b |
文献タイトル (日本語) |
Tolfenamic acidとカフェインの片頭痛における治療 |
目的 |
片頭痛急性期治療における tolfenamic acidとカフェインの有効性を評価する |
研究デザイン |
Double-blind randomized cross-over study |
研究施設 |
Department of Clinical Pharmacology, University of Helsinki , Finland . Department of Neurology, University of Turku , Turku , Finland . Tokola, Medica Pharmaceutical Co Ltd, Helsinki , Finland . |
対象患者 |
49名の片頭痛患者(男性3名,女性46名) |
介入 |
Tolfenamic acid(200mg),カフェイン(100mg),メトクロプラミド(10mg),tolfenamic acid+カフェイン(200mg+100mg),tolfenamic acid+メトクロプラミド(200mg+10mg),プラセボを対象患者に投与.計482回の片頭痛発作を評価. |
結果 |
|
結論 |
NSAIDsである tolfenamic acidはメトクロプラミドやカフェインと併用することにより片頭痛急性期治療において有効性を発揮する.カフェイン,メトクロプラミドともに単独での効果は低い. |
コメント |
中規模の RCT.IHS基準より以前の研究であり,対象の診断や均一性に関して情報が少ない. |
備考1 |
Publication Types:
|
備考2 |
PM: 6984358 |
作成者 |
荒木治子/竹島多賀夫 |